IFNA2 and melanoma: PEG-IFN-α2a has been shown to induce HBeAg seroconversion, a marker of sustained remission in chronic hepatitis B [224, 225], while PEG-IFN-α2b significantly improved relapse-free survival in high-risk melanoma patients [226].